ALLEGAN, Mich., Oct. 9, 2013 /PRNewswire/ -- Perrigo Company (NYSE, TASE: PRGO) today announced that it has scheduled a shareholder meeting for Monday, November 18, 2013 in connection with Perrigo's proposed previously announced acquisition of Elan Corporation, plc (NYSE: ELN) ("Elan").
Perrigo's special meeting of shareholders will be held on November 18, 2013 at 10:00 a.m. at Perrigo's headquarters at 490 Eastern Avenue in Allegan, Michigan. The meeting is being held to seek shareholder adoption of the transaction agreement and approval of the merger and related matters.
Holders of Perrigo common stock of record as at 5.00 p.m. Eastern Standard Time on October 15, 2013 will be entitled to attend and vote at the meeting.The Company expects to begin mailing a joint proxy statement/prospectus to its shareholders in the coming days. The joint proxy statement/prospectus will provide information for shareholders, as well as instructions for shareholders on how to vote their shares. About Perrigo From its beginnings as a packager of generic home remedies in 1887, Allegan, Michigan-based Perrigo Company has grown to become a leading global provider of quality, affordable healthcare products. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of logistics operations have evolved over the years to include the United States, Israel, Mexico, the United Kingdom, India, China and Australia. Visit Perrigo on the Internet ( http://www.perrigo.com). No Offer or Solicitation This announcement is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.